Prof. Kaj Blennow Presents Promising Results on Biomarkers for Early Diagnosis of Alzheimer's Disease Using Ciphergen's SELDI Pr
July 22 2004 - 5:15PM
PR Newswire (US)
Prof. Kaj Blennow Presents Promising Results on Biomarkers for
Early Diagnosis of Alzheimer's Disease Using Ciphergen's SELDI
ProteinChip(R) System Study and Data Presented During Plenary
Lecture at the 9th International Conference on Alzheimer's Disease
FREMONT, Calif., July 22 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) announced today that Prof. Kaj
Blennow from the University of Gothenburg presented encouraging
data from a comprehensive clinical study of human cerebral spinal
fluid (CSF) comparing very mild Alzheimer's Disease patients with
normal individuals and non-AD dementia controls comprising a total
of 236 samples. Scientists at Ciphergen's Diagnostics Division
discovered over 40 biomarkers that were either increased or
decreased in Alzheimer's Disease and considered statistically
meaningful. These biomarkers encompass many different aspects of AD
neuropathology which make them potentially useful for further
research into disease mechanism. Using multi-biomarker
combinations, initial assays were developed that yielded diagnostic
performance of approximately 86% accuracy in detecting early stage
Alzheimer's Disease. Such assays, when confirmed in validation
studies, may prove useful to physicians in differentiating AD from
other forms of dementia as well as by pharmaceutical companies for
therapeutic monitoring assays in both pre-clinical and clinical
development. Follow-on studies are underway in CSF and serum
samples of pathology confirmed cases. Prof. Blennow stated, "SELDI
is a powerful method in the search for CSF biomarkers and it picked
up biomarkers previously missed by other proteomic methods. We have
generated promising results both for Alzheimer's Disease and
Frontotemporal Dementia, and are identifying proteins clearly
linked to the pathogenesis." "Ciphergen's Diagnostics Division
fully intends to pursue translating these novel biomarkers into
multi-biomarker SELDI-based assays for the diagnosis and treatment
monitoring of Alzheimer's Disease," stated Gail S. Page, President
of Ciphergen's Diagnostics Division. Working with collaborators and
well characterized sample collections from the University of Kuopio
and Sahlgren's University Hospital, in approximately 4 months a
scientific team from Ciphergen Diagnostics' Biomarker Discovery
Center(R) laboratory in Copenhagen discovered 44 biomarkers (P
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024